|
1
|
Hedinger C, Williams E and Sobin L:
Histological typing of thyroid tumour. (2nd). World Health
Organization. (New York, NY). 15–17. 1993.
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen AY, Jemal A and Ward EM: Increasing
incidence of differentiated thyroid cancer in the United States,
1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lim H, Devesa SS, Sosa JA, Check D and
Kitahara CM: Trends in thyroid cancer incidence and mortality in
the United States, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nilubol N and Kebebew E: Should small
papillary thyroid cancer be observed? A population-based study.
Cancer. 121:1017–1024. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vrachimis A, Wenning C, Gerß J, Dralle H,
Vaez Tabassi M, Schober O and Riemann B; MSDS study Group, : Not
all DTC patients with N positive disease deserve the attribution
‘high risk’. Contribution of the MSDS trial. J Surg Oncol.
112:9–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anderson KL Jr, Youngwirth LM, Scheri RP,
Stang MT, Roman SA and Sosa JA: T1a versus T1b differentiated
thyroid cancers: Do we need to make the distinction? Thyroid.
26:1046–1052. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP, Talamonti MS and Sturgeon C: Extent of surgery
affects survival for papillary thyroid cancer. Ann Surg.
246:375–381; discussion 381–374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edge SB and Compton CC: The american joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. (Eighth). Springer.
(New York, NY). 873–887. 2017.PubMed/NCBI
|
|
11
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The american thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chereau N, Tresallet C, Noullet S,
Godiris-Petit G, Tissier F, Leenhardt L and Menegaux F: Does the T1
subdivision correlate with the risk of recurrence of papillary
thyroid cancer? Langenbecks Arch Surg. 401:223–230. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang LY, Nixon IJ, Palmer FL, Thomas D,
Tuttle RM, Shaha AR, Patel SG, Shah JP and Ganly I: Comparable
outcomes for patients with pT1a and pT1b differentiated thyroid
cancer: Is there a need for change in the AJCC classification
system? Surgery. 156:1484–1490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rossi R, Roti E, Trasforini G, Pansini G,
Cavazzini L, Zatelli MC, Pearce EN, Braverman LE and Uberti EC:
Differentiated thyroid cancers 11–20 mm in diameter have clinical
and histopathologic characteristics suggesting higher
aggressiveness than those ≤10 mm. Thyroid. 18:309–315. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moher D, Shamseer L, Clarke M, Ghersi D,
Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-PGroup,
: Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ito Y, Masuoka H, Fukushima M, Inoue H,
Kihara M, Tomoda C, Higashiyama T, Takamura Y, Kobayashi K, Miya A
and Miyauchi A: Excellent prognosis of patients with solitary
T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and
elective lymph node dissection without radioiodine therapy. World J
Surg. 34:1285–1290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pellegriti G, Scollo C, Lumera G,
Regalbuto C, Vigneri R and Belfiore A: Clinical behavior and
outcome of papillary thyroid cancers smaller than 1.5 cm in
diameter: Study of 299 cases. J Clin Endocrinol Metab.
89:3713–3720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barbaro D, Simi U, Meucci G, Lapi P,
Orsini P and Pasquini C: Thyroid papillary cancers: Microcarcinoma
and carcinoma, incidental cancers and non-incidental cancers-are
they different diseases? Clin Endocrinol (Oxf). 63:577–581. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reddy RM, Grigsby PW, Moley JF and Hall
BL: Lymph node metastases in differentiated thyroid cancer under 2
cm. Surgery. 140:1050–1054; discussion 1054–1055. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krämer JA, Schmid KW, Dralle H, Dietlein
M, Schicha H, Lerch H, Gerss J, Frankewitsch T, Schober O and
Riemann B; MSDS study Group, : Primary tumour size is a prognostic
parameter in patients suffering from differentiated thyroid
carcinoma with extrathyroidal growth: Results of the MSDS trial.
Eur J Endocrinol. 163:637–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nixon IJ, Ganly I, Patel S, Palmer FL,
Whitcher MM, Tuttle RM, Shaha AR and Shah JP: The impact of
microscopic extrathyroid extension on outcome in patients with
clinical T1 and T2 well-differentiated thyroid cancer. Surgery.
150:1242–1249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ibrahimpasic T, Nixon IJ, Palmer FL,
Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP and Ganly I:
Undetectable thyroglobulin after total thyroidectomy in patients
with low- and intermediate-risk papillary thyroid cancer-is there a
need for radioactive iodine therapy? Surgery. 152:1096–1105. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Avram AM, Fig LM, Frey KA, Gross MD and
Wong KK: Preablation 131-I scans with SPECT/CT in postoperative
thyroid cancer patients: What is the impact on staging? J Clin
Endocrinol Metab. 98:1163–1171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smith JA, Sharma N, Nankivell P and
Watkinson JC: The presentation, natural history and outcome of T1
a/b thyroid cancer with regard to new grading systems. Eur Arch
Otorhinolaryngol. 272:439–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Momesso DP, Vaisman F, Caminha LS, Pessoa
CH, Corbo R and Vaisman M: Surgical approach and radioactive iodine
therapy for small well-differentiated thyroid cancer. J Endocrinol
Invest. 37:57–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS,
Song DE, Hong SJ, Shong YK and Kim WB: Effects of low-dose and
high-dose postoperative radioiodine therapy on the clinical outcome
in patients with small differentiated thyroid cancer having
microscopic extrathyroidal extension. Thyroid. 24:820–825. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baek HJ, Kim DW and Ryu JH: Association
between TNM staging system and histopathological features in
patients with papillary thyroid carcinoma. Endocrine. 48:589–594.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun R, Zhang H, Liu K, Fan J, Li G, Song X
and Li C: Clinicopathologic predictive factors of cervical lymph
node metastasis in differentiated thyroid cancer. Acta
Otorrinolaringol Esp. 69:149–155. 2018.(In English, Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aydin Buyruk B, Kebapci N, Yorulmaz G,
Buyruk A and Kebapci M: An evaluation of clinicopathological
factors effective in the development of central and lateral lymph
node metastasis in papillary thyroid cancer. J Natl Med Assoc.
110:384–390. 2018. View Article : Google Scholar : PubMed/NCBI
|
